Junkosha plans new medical plant by 2025
May 26, 2023
February 8, 2023 By MDO Staff
A Junkosha associate assessing product [Photo courtesy of Junkosha]
As a sector, medical technology is now more than ever an essential source of innovation that continually drives new interventional therapies. The devices and the components that enable new treatments constitute a vital market for patient wellbeing. It is therefore critical the sector responds to not only build a resilient supply chain, but also continues to make sure that interventional medical products are always available in order to serve the needs of customers and improve patient care long-term.
Joe Rowan, President & CEO of USA and Europe for Junkosha, explains: “In response to the ongoing market disruption, Junkosha is continuing to aggressively invest in new capacity and is in the process of installing and validating new equipment as part of its long-term roll-out program. Over the next two years, Junkosha will be making a substantial investment into its medical component manufacturing plants, with the aim to multiply output by a factor of up to four times. Overall, our commitment to supporting the supply of fluoropolymer components to this vital sector remains absolute. We believe that providing the necessary transparency will enable device manufacturers to make informed decisions regarding inventory management.
Alongside its ambitious expansion activities, Junkosha is also continuing to abide by its Customer Charter, which it launched in September 2022. The Customer Charter describes Junkosha’s aspiration to be the best long-term partner by working alongside customers to fulfil their unmet needs.
“Junkosha’s Charter provides our customers with a blueprint for what they can expect from our teams. It also outlines a framework from which our teams can act quickly while exercising judgement that is consistent with our brand values,” concludes Rowan.
Junkosha’s Customer Service Charter: Our Promise to CustomersBuilding on our 68-year legacy, we have a long-standing pedigree of technology innovation and being easy to do business with. Based on this, our aspiration is to be the best long-term partner by working alongside our customers to fulfil their unmet needs. We promise to conduct ourselves according to the following principles:
RESPONSIVEThe ability to respond to each customer’s needs and questions. At the heart of this is the desire to collaborate effectively with partners and to be easy to do business with. Key attributes we aspire to include:
FIRST CLASSDoing the best we can do not only in pursuing the highest quality standards but also in every aspect of our business interactions. Key attributes include:
ENABLINGWe enable our customers to take their technologies to the next level.
About JunkoshaJunkosha are pioneers of sophisticated fluoropolymer application technologies across medical device and microwave interconnect sectors. With three operations in Japan, including its headquarters as well as sites in the US, UK and China, it is one of the best kept advanced technology secrets outside of Japan. The company provides tube and fitting products, including generic resin tubes, fluoropolymer tubes, high-barrier tubes, flexible multi-layered tubes, industrial hoses, degassing modules, heat-shrinkable tubes, and the market leading peelable heat shrink tubes. It also provides wire and cable products, including microwave interconnects, robot cables, high data rate cables, camera link cable assemblies, ultrafine coaxial cables and assemblies, cables for clean environments, and general wires and cables.
The opinions expressed in this news release are the author’s only and do not necessarily reflect those of Medical Design & Outsourcing or its employees.Junkosha Plans New Medical Plant by 2025 as Expansion Strategy AcceleratesRESPONSIVEFIRST CLASSENABLINGAbout JunkoshaThe opinions expressed in this news release are the author’s only and do not necessarily reflect those of Medical Design & Outsourcing or its employees.